Photo illustration by Jakub Porzycki/NurPhoto via AP Images
May 15, 2024 10:42 AM EDTUpdated 01:40 PM
R&D

Re­searchers con­sid­er why We­govy pro­vides heart ben­e­fits be­yond weight loss

Lei Lei Wu

News Reporter

Katherine Lewin

News Reporter

The car­dio­vas­cu­lar ben­e­fits of No­vo Nordisk’s block­buster weight loss drug We­govy are not de­pen­dent on the amount of weight pa­tients lost, ac­cord­ing to a new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times